STIM Quote, Financials, Valuation and Earnings

Delcath Systems has a net margin of -56.29% compared to Neuronetics's net margin of -22.5%. Neuronetics's return on equity of -178.53% beat Delcath Systems's return on equity of -117.89%.

Neuronetics has a consensus price target of $6.83, signalling upside risk potential of 93.58%. On the other hand Delcath Systems has an analysts' consensus of $22.50 which suggests that it could grow by 104.4%. Given that Delcath Systems has higher upside potential than Neuronetics, analysts believe Delcath Systems is more attractive than Neuronetics.

Neuronetics has a beta of 1.975, which suggesting that the stock is 97.503% more volatile than S&P 500. In comparison Delcath Systems has a beta of 0.853, suggesting its less volatile than the S&P 500 by 14.729%.

Neuronetics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Delcath Systems offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Neuronetics pays -- of its earnings as a dividend. Delcath Systems pays out -- of its earnings as a dividend.

Neuronetics quarterly revenues are $22.5M, which are larger than Delcath Systems quarterly revenues of $15.1M. Neuronetics's net income of -$12.7M is lower than Delcath Systems's net income of -$3.4M. Notably, Neuronetics's price-to-earnings ratio is -- while Delcath Systems's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Neuronetics is 1.50x versus 8.70x for Delcath Systems. Usually stocks with elevated PS ratios are considered overvalued.

Exact Sciences has a net margin of -56.29% compared to Neuronetics's net margin of -121.19%. Neuronetics's return on equity of -178.53% beat Exact Sciences's return on equity of -34.11%.

Neuronetics has a consensus price target of $6.83, signalling upside risk potential of 93.58%. On the other hand Exact Sciences has an analysts' consensus of $68.47 which suggests that it could grow by 60.92%. Given that Neuronetics has higher upside potential than Exact Sciences, analysts believe Neuronetics is more attractive than Exact Sciences.

Neuronetics has a beta of 1.975, which suggesting that the stock is 97.503% more volatile than S&P 500. In comparison Exact Sciences has a beta of 1.136, suggesting its more volatile than the S&P 500 by 13.608%.

Neuronetics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Exact Sciences offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Neuronetics pays -- of its earnings as a dividend. Exact Sciences pays out -- of its earnings as a dividend.

Neuronetics quarterly revenues are $22.5M, which are smaller than Exact Sciences quarterly revenues of $713.4M. Neuronetics's net income of -$12.7M is higher than Exact Sciences's net income of -$864.6M. Notably, Neuronetics's price-to-earnings ratio is -- while Exact Sciences's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Neuronetics is 1.50x versus 2.84x for Exact Sciences. Usually stocks with elevated PS ratios are considered overvalued.

Illumina has a net margin of -56.29% compared to Neuronetics's net margin of 16.94%. Neuronetics's return on equity of -178.53% beat Illumina's return on equity of -35.09%.

Neuronetics has a consensus price target of $6.83, signalling upside risk potential of 93.58%. On the other hand Illumina has an analysts' consensus of $129.24 which suggests that it could grow by 74.28%. Given that Neuronetics has higher upside potential than Illumina, analysts believe Neuronetics is more attractive than Illumina.

Neuronetics has a beta of 1.975, which suggesting that the stock is 97.503% more volatile than S&P 500. In comparison Illumina has a beta of 1.376, suggesting its more volatile than the S&P 500 by 37.551%.

Neuronetics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Illumina offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Neuronetics pays -- of its earnings as a dividend. Illumina pays out -- of its earnings as a dividend.

Neuronetics quarterly revenues are $22.5M, which are smaller than Illumina quarterly revenues of $1.1B. Neuronetics's net income of -$12.7M is lower than Illumina's net income of $187M. Notably, Neuronetics's price-to-earnings ratio is -- while Illumina's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Neuronetics is 1.50x versus 2.70x for Illumina. Usually stocks with elevated PS ratios are considered overvalued.

Star Equity Holdings has a net margin of -56.29% compared to Neuronetics's net margin of -14.37%. Neuronetics's return on equity of -178.53% beat Star Equity Holdings's return on equity of -17.45%.

Neuronetics has a consensus price target of $6.83, signalling upside risk potential of 93.58%. On the other hand Star Equity Holdings has an analysts' consensus of $10.00 which suggests that it could grow by 356.62%. Given that Star Equity Holdings has higher upside potential than Neuronetics, analysts believe Star Equity Holdings is more attractive than Neuronetics.

Neuronetics has a beta of 1.975, which suggesting that the stock is 97.503% more volatile than S&P 500. In comparison Star Equity Holdings has a beta of 0.668, suggesting its less volatile than the S&P 500 by 33.205%.

Neuronetics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Star Equity Holdings offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Neuronetics pays -- of its earnings as a dividend. Star Equity Holdings pays out -19.54% of its earnings as a dividend.

Neuronetics quarterly revenues are $22.5M, which are larger than Star Equity Holdings quarterly revenues of $17.1M. Neuronetics's net income of -$12.7M is lower than Star Equity Holdings's net income of -$2.5M. Notably, Neuronetics's price-to-earnings ratio is -- while Star Equity Holdings's PE ratio is 0.75x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Neuronetics is 1.50x versus 0.13x for Star Equity Holdings. Usually stocks with elevated PS ratios are considered overvalued.